IQVIA™ Real-World Insights Bibliography

The CLARION study: first report on safety findings in patients newly initiating treatment with cladribine tablets or fingolimod for multiple sclerosis
Author(s): Helmut Butzkueven, Jan Hillert, Merja Soilu-Hänninen, Tjalf Ziemssen, Jens Kuhle, Stig Wergeland, Melinda Magyari, Joseph R. Berger, Nicholas Moore, Aida Aydemir, Irene Bezemer & Meritxell Sabidó
Affiliations(s): "a Department of Neuroscience, Central Clinical School, Monash University, Melbourne, VIC, Australia; b The Alfred Hospital, Melbourne, VIC, Australia; c Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; d Turku University Hospital Neurocenter and Division of Clinical Neurosciences, University of Turku, Turku, Finland; e Center of Clinical Neuroscience, Department of Neurology, Dresden University of Technology, Dresden, Germany; f Multiple Sclerosis Center and Research Center for Clinical Neuroimmunology and Neuroscience (RC2NB), Departments of Biomedicine and Clinical Research, University Hospital and University of Basel, Basel, Switzerland; g Department of Neurology, University Hospital and University of Basel, Basel, Switzerland; h Norwegian MS Registry and Biobank, Department of Neurology, Haukeland University Hospital, Bergen, Norway; i Department of Clinical Medicine, University of Bergen, Bergen, Norway; j Danish Multiple Sclerosis Center and the Danish Multiple Sclerosis Registry, Department of Neurology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark; k Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; l Bordeaux PharmacoEpi (BPE), Universit?e de Bordeaux, Bordeaux, France; m EMD Serono Research & Development Institute, Inc, Billerica, MA, USA, an affiliate of Merck KGaA; n Global Epidemiology, IQVIA, Amsterdam, The Netherlands; o Merck Healthcare KGaA, Darmstadt, Germany"
Publication(s): 
Document Type(s): Article,
Countries: Australia, Denmark, Finland, Germany, Norway, Sweden, Switzerland, Turkey,
Click here for the abstract
C:
Y:
Comparative Effectiveness & Health Technology Assessment, Drug safety, Neurological disorders,
2023
  L:
A:
English
clinical setting: Secondary care, Epidemiological study, Population Based Study,
  Add to report
 
 
Burden of caregivers of patients with neuronopathic and non-neuronopathic Gaucher disease in Japan: a survey-based study
Author(s): Yuta Koto 1, Aya Narita 2, Shinichi Noto 3, Masafumi Okada 4, Midori Ono 5, Terumi Baba 5, Rieko Sagara 5, Norio Sakai 1 (rwesheorj 4)
Affiliations(s): 1) Child Healthcare and Genetic Science Laboratory, Division of Health Sciences, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita-shi, Osaka 565-0871, Japan 2) Division of Child Neurology, Institute of Neurological Science, Tottori University Faculty of Medicine, 86 Nishi-cho, Yonago-shi, Tottori 683-8503, Japan 3) Department of Rehabilitation, Niigata University of Health and Welfare, 1398 Shimami-cho, Kita-ku, Niigata-shi, Niigata 950-3198, Japan 4) Real-World Evidence Solutions & HEOR, IQVIA Solutions Japan K.K., 4-10-18 Takanawa, Minato-ku, Tokyo 108-0074, Japan 5) Japan Medical Office, Takeda Pharmaceutical Company Limited, 2-1-1 Nihonbashi-Honcho, Chuo-ku, Tokyo 103-8688, Japan
Publication(s):  Molecular Genetics and Metabolism Reports
Document Type(s): Article, Online article,
Countries: Japan,
Click here for the abstract
C:
Y:
Endocrinology, Neurological disorders,
2023
  L:
A:
English
Patient questionnaire, Survey research,
  Add to report
 
 
Prevalence of subjective memory complaints: Population study in Spain
Author(s): Javier González García a∗, Eva García Aguilar a, Tatiana Vilchez Quinoa, Marta Blanco b and Carmen Barrull b
Affiliations(s): a Departamento Médico, ITF Research Pharma, SLU, Alcobendas, Madrid, España b IQVIA España, Barcelona, España
Publication(s):  Revista Española de Geriatría y Gerontología
Document Type(s): Article,
Countries: Spain,
Click here for the abstract
C:
Y:
Mental health, Neurological disorders,
2023
  L:
A:
Spanish
  Add to report
 
 
The CLARION study design and status update: a long-term, registry-based study evaluating adverse events of special interest in patients with relapsing multiple sclerosis newly started on cladribine tablets
Author(s): Helmut Butzkueven 1 2, Nicholas Moore 3, Aida Aydemir 4, Jaak Sõnajalg 5, Irene Bezemer 6, Pasi Korhonen 7, Meritxell Sabidó 8, CLARION Study Group
Affiliations(s): 1Department of Neuroscience, Central Clinical School, Monash University, Melbourne, Australia. 2The Alfred Hospital, Melbourne, Australia. 3Bordeaux PharmacoEpi (BPE), Université de Bordeaux, Bordeaux, France. 4Global Biostatistics, EMD Serono Research & Development Institute, Inc, Billerica, MA, USA (an affiliate of Merck KGaA). 5Global Database Studies, IQVIA, Tartu, Estonia. 6Global Epidemiology and Outcomes Research, IQVIA, Amsterdam, The Netherlands. 7IQVIA (former EPID Research), Espoo, Finland. 8Global Epidemiology, Merck Healthcare KGaA, Darmstadt, Germany.
Publication(s):  Current Medical Research and Opinion, DOI: 10.1080/03007995.2022.2059977
Document Type(s): Article,
Countries: Australia, Denmark, Finland, Germany, Norway, Sweden, Switzerland, Turkey,
Click here for the abstract
C:
Y:
Drug safety, Neurological disorders,
2022
  L:
A:
English
clinical setting: Secondary care, Epidemiological study, Observational study, Population Based Study, Retrospective database analysis,
  Add to report
 
 
A real-world, observational study of erenumab for migraine prevention in Canadian patients
Author(s): Werner J Becker 1, Sian Spacey 2, Elizabeth Leroux 3, Rose Giammarco 4, Jonathan Gladstone 5, Suzanne Christie 6, Arash Akaberi 7, G Sarah Power 8, Jagdeep K Minhas 9, Johanna Mancini 7, Driss Rochdi 10, Ayca Filiz 10, Natacha Bastien 10
Affiliations(s): 1Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada. 2Division of Neurology, University of British Columbia, Vancouver, British Columbia, Canada. 3Brunswick Medical Center, Montreal, Quebec, Canada. 4Hamilton Headache Clinic, Hamilton, Ontario, Canada. 5Gladstone Headache Clinic, Toronto, Ontario, Canada. 6Ottawa Headache Centre Inc., Ottawa, Ontario, Canada. 7IQVIA Solutions Canada Inc., Montreal, Quebec, Canada. 8IQVIA Solutions Canada Inc., Mississauga, Ontario, Canada. 9IQVIA Solutions Canada Inc., Ottawa, Ontario, Canada. 10Novartis Canada, Dorval, Quebec, Canada.
Publication(s):  Headache. 2022 Apr;62(4):522-529. doi: 10.1111/head.14291. Epub 2022 Apr 10. PMID: 35403223.
Document Type(s): Article,
Countries: Canada,
Click here for the abstract
C:
Y:
Neurological disorders,
2022
  L:
A:
English
Observational study,
  Add to report
 
 
The longitudinal relationship between fatigue, depression, anxiety, disability, and adherence with cognitive status in patients with early multiple sclerosis treated with interferon beta-1a
Author(s): Hanne van Ballegooijen, Karin van der Hiele, Christian Enzinger, Gert de Voer, Leo H. Visser, on behalf of the CONFIDENCE Study Group
Affiliations(s): IQVIA Netherlands, Real World Evidence, Netherlands b Department of Psychology, Health, Medical and Neuropsychology Unit, Leiden University, Leiden, Netherlands c Medical University of Graz, Graz, Austria d Merck BV, Schiphol-Rijk, The Netherlands, an affiliate of Merck KGaA, Germany e St Elisabeth Tweesteden Hospital, Tilburg, the Netherlands
Publication(s):  eNeurologicalSci, Volume 28, 2022, 100409, ISSN 2405-6502, https://doi.org/10.1016/j.ensci.2022.100409. (https://www.sciencedirect.com/science/article/pii/S2405650222000181)
Document Type(s): Article,
Countries: Austria, Belgium, Netherlands , Slovakia,
Click here for the abstract
C:
Y:
Drug safety, Drug Utlization Study, Neurological disorders,
2022
  L:
A:
English
Clinical setting: hospital, clinical setting: Secondary care, Epidemiological study, Population Based Study, Prospective study,
  Add to report
 
 
Nutritional status and use of health resources after the implementation of an enteral nutrition program by PEG probe for neurological patients with home hospitalization
Author(s): Blanco Ramos B, Lopez Garcia B, Gómez Bellvert N.
Affiliations(s): Hospital General Universitario de Elda (Alicante). Carretera Elda-Sax SN. 03600
Publication(s):  Nutr Hosp . 2022 Jun 24;39(3):489-498. doi: 10.20960/nh.03813.
Document Type(s): Article,
Countries: Spain,
Click here for the abstract
C:
Y:
Neurological disorders, Nutritional Disorders,
2022
  L:
A:
Spanish
Clinical setting: hospital, Cost benefit, Observational study, Population Based Study, Quality of life,
  Add to report
 
 
Real picture of patients with Charcot-Marie-Tooth disease in Japan: IQVIA Claims Database
Author(s): Yuki Kado 1, Yuya Tamai 1, Seok-Won Kim 1, Sven Demiya 1 (rwesheorj 1)
Affiliations(s): 1) Real World Evidence Solutions & HEOR, IQVIA Solutions Japan K.K., Tokyo, Japan
Publication(s):  ISPOR
Document Type(s): Conference, Poster, Presentation,
Countries: Japan,
Click here for the abstract
C:
Y:
Neurological disorders,
2022
  L:
A:
English
Database Study,
  Add to report
 
 
Database study on background information and first-line drug treatment of patients with early-onset Alzheimer's disease
Author(s): Shingo Wada 1, Ryosuke Miyagawa 2, Ai Inada 2, Yugo Namiya 2, Komei Iwasaki 2, Ryohei Kobayashi 2, Kaiwei Yan 1 (rwesheorj 1)
Affiliations(s): 1) IQVIA Solutions Japan K.K. 2) IQVIA Services Japan K.K.
Publication(s):  The 27th Annual Meeting of the Japanese Society for Pharmacoepidemiology
Document Type(s): Conference, Oral presentation,
Countries: Japan,
Click here for the abstract
C:
Y:
Neurological disorders,
2022
  L:
A:
Japanese
Database Study,
  Add to report
 
 
Multimodal strategy to rescue the brain in mild cognitive impairment: Ketogenic oral nutrition supplementation with B vitamins and aerobic exercise
Author(s): Stephen C Cunnane 1, Russell H Swerdlow 2, Marco Inzitari 3 4, Gloria Olaso-Gonzalez 5, José Viña 5
Affiliations(s): 1Research Center on Aging and Department of Medicine, Université de Sherbrooke, Sherbrooke, Quebec, Canada. 2University of Kansas Alzheimer's Disease Center, KUMC Neurodegenerative Disorders Program, University of Kansas School of Medicine, Lawrence, Kansas, USA. 3REFiT Barcelona Research Group, Parc Sanitari Pere Virgili and Vall d'Hebrón Institute of Research, Barcelona, Spain. 4Department of Health Sciences, Universitat Oberta de Catalonia, Barcelona, Spain. 5Department of Physiology, Faculty of Medicine, Universitat de València, Valencia, Spain.
Publication(s): 
Document Type(s): Article,
Countries: 
Click here for the abstract
C:
Y:
Neurological disorders, Nutritional Disorders, Public Health,
2022
  L:
A:
English
Review,
  Add to report
 
 
 1 of 23 Next Page Last Page